Universal approach to pharmacokinetic monitoring of immunosuppressive agents in children

被引:62
作者
Filler, G
Feber, J
Lepage, N
Weiler, G
Mai, I
机构
[1] Univ Ottawa, Div Pediat Nephrol, Childrens Hosp Eastern Ontario, Dept Pediat, Ottawa, ON K1H 8L1, Canada
[2] Univ Ottawa, Childrens Hosp Eastern Ontario, Dept Lab Med, Ottawa, ON K1H 8L1, Canada
[3] Humboldt Univ, Charite, Berlin, Germany
关键词
cyclosporin; tacrolimus; mycophenolate mofetil; mycophenolic acid; pharmacokinetics; area under the curve;
D O I
10.1034/j.1399-3046.2002.02039.x
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Current data indicate that pharmacokinetic (PK) monitoring of cyclosporin microemulsion (CsA) should be performed using the 2-h concentration (C2), that tacrolimus (Tac) is commonly monitored using the trough level, and mycophenolate mofetil (MMF) should be monitored using the 1-h (C1), 2-h (C2) and 6-h (C6) concentrations. The three differing time-point requirements are cumbersome, and we aimed to develop universal guidelines for all three drugs using a large number of full PK profiles in children. One-hundred and twenty two stable pediatric patients, receiving either CsA ( 165 PK profiles, 69 patients, 24 with concomitant MMF) or Tac (122 PK profiles, 53 patients, 18 with MMF) were analyzed retrospectively. Pearson r for the CsA C2 was 0.90 [95% confidence interval(CI) : 0.86-0.92], for Tac C2 r was 0.86 (95% CI: 0.80-0.90), and for MPA C2 r was 0.77 (95% CI: 0.68-0.83), respectively. For MPA, at least three time-points are required to accurately estimate the area under the concentration time curve (AUC), and C1, C2 and C6 serve as best markers. Excellent AUC estimations could be obtained from a limited sampling strategy from C1, C2 and C6 or C0, C1, C2 and C4 with clinically acceptable errors for all three drugs. The AUC can be estimated with great precision by using an identical approach for all three drugs. Target AUCs for a given time-point after transplantation remain to be established.
引用
收藏
页码:411 / 418
页数:8
相关论文
共 28 条
[1]   IMMUNOSUPPRESSIVE AND OTHER EFFECTS OF MYCOPHENOLIC-ACID AND AN ESTER PRODRUG, MYCOPHENOLATE MOFETIL [J].
ALLISON, AC ;
EUGUI, EM .
IMMUNOLOGICAL REVIEWS, 1993, 136 :5-28
[2]  
Bauer S., 1996, Naunyn-Schmiedeberg's Archives of Pharmacology, V353, pR149
[3]  
CLARDY CW, 1988, CLIN CHEM, V34, P2012
[4]   USE OF CYCLOSPORINE IN PEDIATRIC RENAL-TRANSPLANT RECIPIENTS [J].
CONLEY, SB ;
FLECHNER, SM ;
ROSE, G ;
VANBUREN, CT ;
BREWER, E ;
KAHAN, BD .
JOURNAL OF PEDIATRICS, 1985, 106 (01) :45-49
[5]  
ETTENGER R, 1997, 16 ANN M AM SOC TRAN
[6]  
Filler G, 1996, LANCET, V348, P1176, DOI 10.1016/S0140-6736(05)65317-2
[7]   Limited sampling strategy for mycophenolic acid area under the curve [J].
Filler, G ;
Mai, I .
THERAPEUTIC DRUG MONITORING, 2000, 22 (02) :169-173
[8]   Abbreviated cyclosporine AUCs on Neoral - the search continues! [J].
Filler, G ;
Mai, I ;
Filler, S ;
Ehrich, JHH .
PEDIATRIC NEPHROLOGY, 1999, 13 (02) :98-102
[9]   Mycophenolate mofetil for rescue therapy in acute renal transplant rejection in children should always be monitored by measurement of trough concentration [J].
Filler, G ;
Ehrich, J .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1997, 12 (02) :374-375
[10]   Pharmacokinetics of tacrolimus (FK 506) in children and adolescents with renal transplants [J].
Filler, G ;
Grygas, R ;
Mai, I ;
Stolpe, HJ ;
Greiner, C ;
Bauer, S ;
Ehrich, JHH .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1997, 12 (08) :1668-1671